Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

15-Year safety check for caribou cell therapy patients

NCT ID NCT05332054

Knowledge-focused Sponsor: Caribou Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observation to understand safety over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Dec 2041

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who received IP in a Caribou-sponsored clinical study, special access program, or IIT and provided informed consent for the LTFS

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment * Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT * Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion. Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-cell lymphoma B-cell non-Hodgkin's lymphoma Hematologic malignancy Lymphoma Lymphoma, non-Hodgkin Non-Hodgkin lymphoma Refractory B-cell non-Hodgkin lymphoma Relapsed non-Hodgkin lymphoma Relapsed/refractory acute myeloid leukemia Relapsed/refractory multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    31 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando

    Orlando, Florida, 32804, United States

  • Atlantic Health System Cancer Care

    Morristown, New Jersey, 07960, United States

  • Augusta University/Georgia Cancer Center

    Augusta, Georgia, 30912, United States

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Baylor Research Institute

    Dallas, Texas, 75246, United States

  • Blood & Marrow Transplant Group of Georgia

    Atlanta, Georgia, 30342, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Honor Health Research Institute

    Scottsdale, Arizona, 85258, United States

  • Huntsman Cancer Institute at the University of Utah

    Salt Lake City, Utah, 84112, United States

  • Icahn School of Medicine at Mt. Sinai

    New York, New York, 10029, United States

  • Levine Cancer Center

    Charlotte, North Carolina, 28204, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40207, United States

  • Oncology Hematology Care

    Cincinnati, Ohio, 45242, United States

  • Regional Cancer Care Associates - Hackensack

    Hackensack, New Jersey, 07601, United States

  • Sarah Cannon Research Institute - TriStar Health

    Nashville, Tennessee, 37203, United States

  • University of Alabama

    Birmingham, Alabama, 35233, United States

  • University of California Irvine

    Irvine, California, 92868, United States

  • University of California San Diego

    La Jolla, California, 92093, United States

  • University of Colorado

    Denver, Colorado, 80045, United States

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa, 52242, United States

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas Southwestern

    Dallas, Texas, 75235, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23284, United States

  • Weill Cornell Medicine

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.